Vivani Medical Inc

Vivani Medical, Inc. (Nasdaq: VANI), formerly Second Sight Medical Products, is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants utilizing its proprietary NanoPortal technology platform. The company's lead asset, NPM-139, is a subdermal semaglutide implant designed to deliver GLP-1 receptor agonist therapy continuously for six to twelve months, targeting chronic weight management and metabolic diseases including obesity and type 2 diabetes. Vivani's implants are designed for once- or twice-yearly administration during a routine primary care office visit, addressing the widespread problem of medication non-adherence that affects approximately 50% of patients. The company also operates a neurostimulation subsidiary, Cortigent, Inc., which develops brain-computer interface devices based on precision neurostimulation technology, including the Orion cortical stimulation system with FDA Breakthrough Device designation for treating blindness. Cortigent is in the process of becoming a standalone publicly traded company through a merger with ClearOne, Inc. Vivani's predecessor company previously marketed the Argus II retinal prosthesis, the first FDA-approved device to treat a rare form of blindness. Updated Aug 13, 2026